Alnylam Pharmaceuticals | ALNY - Ordinary Share Capital


Alnylam Pharmaceuticals reported $132.38M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amgen USD 539M 1000K Dec/2025
Arrowhead Research USD 135.7M 2.44M Sep/2025
BioCryst Pharmaceuticals USD 1.9M 3K Sep/2023
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Incyte USD 198.46M 2.33M Dec/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Novartis USD 1.92B 17.06M Sep/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Takeda JPY 1.58B 2K Dec/2025
Tectonic Therapeutic USD 14.86M 111.83K Dec/2024
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025
Xencor USD 71.34M 46K Sep/2025